Results 121 to 130 of about 878,067 (286)
Twenty years of inhaler therapy: A nationwide drug utilization study
Aims This study aimed to map nationwide trends and prescribing patterns in inhaler use from 2004 to 2023. In light of evolving clinical guidelines and attention to the environmental impact of inhalers within recent years, we also examined variation in prescribing behaviour and patient‐level treatment choices. Methods Using nationwide health registries,
Katrine Bitsch Johansen +5 more
wiley +1 more source
Inhalation injury is defined as airway or pulmonary parenchymal injury caused by inhalation of smoke, toxin and chemical gases. Frequently, it results from inhalation of smoke and incomplete products of combustion.
Yuncu, Gökhan, Üçvet, Ahmet
core
ABSTRACT Aims Imatinib improves hemodynamics in pulmonary arterial hypertension (PAH), but dose‐dependent toxicity has limited its clinical development. We aimed to quantify the dose–efficacy–toxicity relationship and evaluate alternative dosing strategies using data from the PIPAH trial.
Medhat M. Said +13 more
wiley +1 more source
Critical physicochemical attributes of chitosan nanoparticles admixed lactose-PEG 3000 microparticles in pulmonary inhalation. [PDF]
Alhajj N +5 more
europepmc +1 more source
In healthy anaesthetized Friesian-Holstein calves, pulmonary hypertension was induced ly means of a continuous intravenous administration of serotonin (0.025 mg/kg body/weight/min).
Sustronck, Bart +11 more
core +1 more source
Aim Londamocitinib (AZD4604) is an inhaled, selective Janus kinase 1 (JAK1) inhibitor in development for asthma. This open‐label, two‐part, phase I clinical study (NCT06157255) used a radiolabelled microtracer approach to evaluate the absolute bioavailability and the absorption, distribution, metabolism and excretion (ADME) of inhaled londamocitinib ...
Camille Riff +12 more
wiley +1 more source
We investigated acute effects of inhalation of hypertonic saline solution (HSS) and oxygen (O2, control exposure) on pulmonary diffusing capacity for nitric oxide (DLNO) and carbon monoxide (DLCO). In a randomized crossover study, 20 healthy, non-smoking
M. Simon +27 more
core +1 more source
Safety and pharmacokinetics of inhaled aloxistatin: A first‐in‐human phase 1 dose escalation trial
Aims Aloxistatin (E64d) is a membrane‐permeable cysteine protease inhibitor prodrug that is converted by esterases to the active metabolite E64c (loxistatin). This first‐in‐human study evaluated the safety, tolerability and pharmacokinetics of single ascending doses of inhaled E64d in healthy volunteers.
Sebastian Fähndrich +24 more
wiley +1 more source
Inhalation injury remains a critical determinant of morbidity and mortality among patients with severe burns, particularly in burn intensive care unit (ICU) settings.
Mohsen Farrokhpour, Niloofar Keikhaei
doaj +1 more source
A soft‐compliant hydrogel cuff coating combines real‐time pressure monitoring with intrinsic antibacterial activity for prophylaxis of ventilator‐associated pneumonia. A flexible pressure‐sensing patch is embedded in the coating to enable wireless dynamic monitoring of endotracheal cuff pressure through Bluetooth.
Jin Chai +11 more
wiley +1 more source

